|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||11.97 - 12.22|
|52 Week Range||8.31 - 24.30|
|PE Ratio (TTM)||-3.68|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
In October 2017, Valeant Pharmaceuticals presented the results of its pivotal Phase 3 long-term extension AMAGINE-2 trial with Siliq.
In 1H17, Valeant Pharmaceuticals International's (VRX) dermatology franchise reported revenues of $322.0 million compared to $380.0 million in 1H16.
In 1H17, Valeant Pharmaceuticals International (VRX) reported revenues of $4.3 billion compared to $4.7 billion in 1H16. In 2Q17, its revenues were $2.2 billion.
A measure called return on corporate capital is revealing — and there’s a free investor tool for research. By Phil van Doorn.
A quick glance at its chart will tell you that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a bargain. But beware. Valeant stock is not now, nor has it ever been, a bargain stock. When you add the debt of $28.6 billion to the market cap of $4.3 billion, you’re looking at a $33 billion company that should have $9 billion in annual sales this year, mostly from Bausch + Lomb, the eye care company acquired in 2013, and it could have less if it keeps selling subsidiaries.
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.
Is it time to shop-the-drop in Shopify Inc (US) (NYSE:SHOP)? If, like me, you demand a good deal but also worry about defective merchandise, then a bull call spread makes plenty of sense in SHOP stock. Andrew Left of Citron Research recently targeted Shopify.
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
Shopify Inc (US) (NYSE:SHOP) shares have lost about 17% of their value since short-sellers Citron Research issued a scathing report that called it an affiliate marketing scam comparable to Herbalife Ltd. (NYSE:HLF). The Canadian e-commerce software company should have called Citron’s claim a compliment, since Herbalife’s value has doubled since hedge fund manager Bill Ackman put out his famous short call almost five years ago. To me, the Citron report looks scary enough to act on. Other InvestorPlace writers disagree.
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, Oct. 16, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,000,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on October 17, 2017 (the "Early Settlement Date"). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.
NEW YORK, NY / ACCESSWIRE / October 16, 2017 / Shares of Celgene Corporation saw a small gain on Friday despite any news, while Valeant Pharmaceuticals saw a loss of roughly 3% despite not having any significant ...
Valeant Pharmaceuticals International Inc (NYSE:VRX), a CAD$4.82B mid-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an agingRead More...
October has been relatively quiet for Valeant Pharmaceuticals Internation (VRX), with little in the way of attention getting news. Yes, there have been some small successes in drug trials, and even a positive note from a Deutsche Bank analyst. Today, however, Valeant's stock has more than doubled its October loss after Wells Fargo's David Maris raised concerns about a lawsuit filed by Depomed (DEPO) over an alleged $20 million in unpaid royalties: In the grand scheme of Valeant’s issues, an unpaid $20 million bill barely rises to the level of investor concern.
Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Valeant Pharmaceuticals International, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
If the names Andrew Left or Citron Research ring a bell, there’s a reason. Left, the lead (and seemingly only) analyst for Citron largely prompted the scrutiny of specialty pharmacy company Philidor, owned by Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
LAVAL, Quebec, Oct. 12, 2017 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis. SILIQ is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
In spring 2016, when many mutual funds and other investors were heaving over shares of Valeant Pharmaceuticals International as if trying to lighten a sinking ship, David Ford, co-founder of distressed-debt ...